Intellia Therapeutics, Inc. NTLA
NASDAQ · United States · Health Technology
$12.12+0.06 (+0.50%)
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Here's how to play leading gene-editing stocks as Anthropic's AI tools make progress in the gene-editing space.
Anthropic says Claude identified a novel enzyme system with characteristics reminiscent of CRISPR
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
CRSP shares closed down 6% on Wednesday, while PRME and EDIT stocks declined 12% and 8%, respectively.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.